Sherif Makar, MD

Sherif Makar, MD

Neuro-Oncologist

Cancer

Dr. Makar

Overview

Sherif Makar, MD, fellowship-trained neuro-oncologist, received his medical degree from the University of South Florida Morsani College of Medicine in Tampa. He completed his residency training in neurology at the University of Florida College of Medicine in Jacksonville, where he was named Outstanding Resident Educator. Dr. Makar also completed a fellowship in the prestigious Neuro-Oncology program at Stanford University. His primary goal is to provide exceptional care for his patients through research and clinical expertise. Dr. Makar is a member of the Stanford Society of Physician Scholars, the Society of Neuro-Oncology and the American Academy of Neurology.

Articles

Successful Intrathecal Rituximab Administration in Refractory Nonteratoma Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report

JOURNAL OF NEUROSCIENCE NURSING

2019

Oligodendrogliomas-Atypical clinical presentations

OLIGODENDROGLIOMA: CLINICAL PRESENTATION, PATHOLOGY, MOLECULAR BIOLOGY, IMAGING, AND TREATMENT

2019

More Publication Information

Education & Training

Education

University of South Florida Morsani College of Medicine, Tampa, FL

Residency

University of Florida College of Medicine, Jacksonville, FL

Fellowship

Stanford University Medical Center, Stanford, CA

Specialty

Medical Oncology

Board Certifications

American Board of Psychiatry and Neurology

Associated Clinical Trials

NCT00887146

Phase III Integraoup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Icon for trial | N0577 Phase III Integraoup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

This study is currently enrolling.

The purpose of this study is to compare the effectiveness of either 1) radiotherapy (RT, radiation therapy) along with temozolomide chemotherapy followed by additional temozolomide chemotherapy (RT + TMZ -> TMZ); or 2) radio ...